TEL
AVIV, Israel, May 18, 2022
/PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB),
(Chemomab), a clinical-stage biotechnology company focused on the
discovery and development of innovative therapeutics for fibrotic
and inflammatory diseases with high unmet need, today announced
that management will participate in the virtual portion of the H.C.
Wainwright Global Investment Conference, which will take
place May 23-26, 2022.
HC Wainwright Global Investment Conference
Date:
Webcast available on demand starting at 7:00am ET May 24 –
May 26, 2022
Format:
Corporate overview webcast
Webcast Link:
https://journey.ct.events/view/47c6f14e-2e3e-4baf-9592-cf2d6c3317f5
Replay:
Available at Chemomab website at
investors.chemomab.com/events
Chemomab is also participating in one-on-one meetings with
investors. For more information, visit
hcwevents.com/globalconference/.
About Chemomab Therapeutics Ltd.
Chemomab is a
clinical-stage biotechnology company focusing on the discovery and
development of innovative therapeutics for fibrotic and
inflammatory diseases with high unmet need. Based on the unique and
pivotal role of the soluble protein CCL24 in promoting fibrosis and
inflammation, Chemomab developed CM-101, a monoclonal antibody
designed to bind and block CCL24 activity. CM-101 has demonstrated
the potential to treat multiple severe and life-threatening
fibrotic and inflammatory diseases. It is currently in Phase 2
trials for primary sclerosing cholangitis and liver fibrosis, with
a Phase 2 trial in systemic sclerosis expected to begin in late
2022.
Contacts:
|
|
Investor
Relations:
|
Media:
|
Irina Koffler
|
Barbara
Lindheim
|
LifeSci Advisors,
LLC
|
Chemomab
Therapeutics
|
Phone: +1
917-734-7387
|
Consulting Vice
President
|
ir@chemomab.com
|
Investor &
Public Relations,
|
|
Strategic
Communications
|
|
Phone: +1
917-355-9234
|
|
barbara@chemomab.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-participate-in-hc-wainwright-global-investment-conference-301549851.html
SOURCE Chemomab Therapeutics, Ltd.